CD163-A specific marker of macrophages in paraffin-embedded tissue samples
CD163-A specific marker of macrophages in paraffin-embedded tissue samples
复制标题
DOI：
10.1309/qhd6yfn81kqxuuh6
复制
发表时间：
2004-11-01
影响因子：
3.5
通讯作者：
Weiss, LM
中科院分区：
文献类型：
--
作者：
Lau, SK;Chu, PG;Weiss, LM
石蜡切片免疫组织化学分析进行使用抗CD 163的单克隆抗体，以评估该抗体的有用性，在确定单核细胞/巨噬细胞谱系在正常和肿瘤条件下的细胞。正常人组织样本和211例造血系统疾病和115例非造血系统肿瘤的样本进行了检查。还评价了针对巨噬细胞相关CD 68抗原的单克隆抗体KP 1和PG-M1的分布以进行比较。除脾白色髓巨噬细胞和生发中心易染体巨噬细胞外，所有正常组织标本的常驻巨噬细胞均观察到CD 163免疫反应。在造血系统疾病和非造血系统肿瘤中，CD 163的表达主要局限于慢性粒单核细胞白血病、组织细胞肉瘤、窦组织细胞增生症伴巨大淋巴结病和沿岸的细胞血管瘤。除1例急性单核细胞白血病外，所有伴单核细胞分化的急性髓性白血病均为CD 163-。大多数髓样肉瘤也是CD 163-。与CD 68抗体相比，CD 163作为单核细胞/巨噬细胞来源疾病的标志物表现出更高的特异性。然而，CD 163表达的免疫组化评价似乎不是确定石蜡切片中AML中单核细胞分化或建立髓样肉瘤诊断的敏感手段。
Paraffin-section immunohistochemical analysis was performed using a monoclonal antibody against CD163 to evaluate the antibody's usefulness in identifying cells of monocyte/macrophage lineage in normal and neoplastic conditions. Normal human tissue samples and samples from 211 hematopoietic disorders and 115 nonhematopoietic neoplasms were examined. The distribution of KP1 and PG-M1, monoclonal antibodies to the macrophage-associated CD68 antigen, also were evaluated for comparison. CD163 immunoreactivity was observed in resident macrophages of all normal tissue samples except splenic white pulp macrophages and germinal center tingible body macrophages. Among hematopoietic disorders and nonhematopoietic neoplasms, CD163 expression was restricted largely to cases of chronic myelomonocytic leukemia, histiocytic sarcoma, sinus histiocytosis with massive lymphadenopathy, and littoral cell angioma. Acute myeloid leukemias (AMLs) with monocytic differentiation were CD163- with the exception of 1 case of acute monoblastic leukemia. Most myeloid sarcomas also were CD163-. Compared with the CD68 antibodies, CD163 demonstrated greater specificity as a marker of disorders of monocyte/macrophage origin. However, immunohistochemical evaluation of CD163 expression does not seem to be a sensitive means of determining monocytic differentiation in AMLs in paraffin sections or establishing a diagnosis of myeloid sarcoma.